Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.

or for maintenance post-GLP-1 cessation,” said Paul Bolno, MD, MBA, President and Chief Executive Officer at Wave Life Sciences. “Additionally, we are excited to introduce three new programs ...

The BIO-Europe conference provides a prestigious platform for Tiziana to highlight its strategic advancements to the biopharma community, as well as to expand its partnerships aimed at accelerating ...

No. 49 / 2024Zealand Pharma Announces Financial Results for the First Nine Months of 2024Continued strong progress across ...

Eli Lilly's product pipeline is anchored by its GLP-1 receptor agonists, Mounjaro (tirzepatide) and Zepbound. These drugs have shown impressive results in treating type 2 diabetes and obesity, ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...